South Korea
· Delayed Price · Currency is KRW KOREA PHARMA Statistics
Total Valuation
KOREA PHARMA has a market cap or net worth of KRW 177.78 billion. The enterprise value is 162.83 billion.
| Market Cap | 177.78B |
| Enterprise Value | 162.83B |
Important Dates
| Earnings Date | n/a |
| Ex-Dividend Date | Dec 27, 2024 |
Share Statistics
KOREA PHARMA has 10.91 million shares outstanding. The number of shares has increased by 10.32% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 10.91M |
| Shares Change (YoY) | +10.32% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 64.77% |
| Owned by Institutions (%) | 0.11% |
| Float | 3.84M |
Valuation Ratios
The trailing PE ratio is 59.12.
| PE Ratio | 59.12 |
| Forward PE | n/a |
| PS Ratio | 2.20 |
| PB Ratio | 2.52 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 42.62 |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 26.83, with an EV/FCF ratio of 39.04.
| EV / Earnings | 54.37 |
| EV / Sales | 2.03 |
| EV / EBITDA | 26.83 |
| EV / EBIT | 50.18 |
| EV / FCF | 39.04 |
Financial Position
The company has a current ratio of 3.10, with a Debt / Equity ratio of 0.41.
| Current Ratio | 3.10 |
| Quick Ratio | 2.18 |
| Debt / Equity | 0.41 |
| Debt / EBITDA | 3.70 |
| Debt / FCF | 6.96 |
| Interest Coverage | 1.64 |
Financial Efficiency
Return on equity (ROE) is 4.63% and return on invested capital (ROIC) is 2.94%.
| Return on Equity (ROE) | 4.63% |
| Return on Assets (ROA) | 2.50% |
| Return on Capital (ROIC) | 2.94% |
| Revenue Per Employee | 600.02M |
| Profits Per Employee | 22.35M |
| Employee Count | 134 |
| Asset Turnover | 0.64 |
| Inventory Turnover | 2.37 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -29.77% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -29.77% |
| 50-Day Moving Average | 17,677.80 |
| 200-Day Moving Average | 19,064.90 |
| Relative Strength Index (RSI) | 40.39 |
| Average Volume (20 Days) | 482,524 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, KOREA PHARMA had revenue of KRW 80.40 billion and earned 2.99 billion in profits. Earnings per share was 275.69.
| Revenue | 80.40B |
| Gross Profit | 35.38B |
| Operating Income | 5.01B |
| Pretax Income | 2.28B |
| Net Income | 2.99B |
| EBITDA | 7.84B |
| EBIT | 5.01B |
| Earnings Per Share (EPS) | 275.69 |
Balance Sheet
The company has 43.97 billion in cash and 29.02 billion in debt, giving a net cash position of 14.94 billion or 1,370.22 per share.
| Cash & Cash Equivalents | 43.97B |
| Total Debt | 29.02B |
| Net Cash | 14.94B |
| Net Cash Per Share | 1,370.22 |
| Equity (Book Value) | 70.52B |
| Book Value Per Share | 6,465.60 |
| Working Capital | 56.23B |
Cash Flow
In the last 12 months, operating cash flow was 5.17 billion and capital expenditures -1.00 billion, giving a free cash flow of 4.17 billion.
| Operating Cash Flow | 5.17B |
| Capital Expenditures | -1.00B |
| Free Cash Flow | 4.17B |
| FCF Per Share | 382.43 |
Margins
Gross margin is 44.00%, with operating and profit margins of 6.24% and 3.72%.
| Gross Margin | 44.00% |
| Operating Margin | 6.24% |
| Pretax Margin | 2.84% |
| Profit Margin | 3.72% |
| EBITDA Margin | 9.75% |
| EBIT Margin | 6.24% |
| FCF Margin | 5.19% |
Dividends & Yields
KOREA PHARMA does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | 18.21% |
| Buyback Yield | -10.32% |
| Shareholder Yield | -10.32% |
| Earnings Yield | 1.69% |
| FCF Yield | 2.35% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
KOREA PHARMA has an Altman Z-Score of 4.36.
| Altman Z-Score | 4.36 |
| Piotroski F-Score | n/a |